Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

Kingjake26 Nov. 14 at 10:48 PM

ACORN CAPITAL ADVISORS, LLC added 428,265 shares (+19.9%) to their portfolio in Q2 2025, for an estimated $2,167,020 $CADL. Some funds added. Some sold. This was a big add

0 · Reply

Kingjake26 Nov. 14 at 10:48 PM

VANGUARD GROUP INC added 219,563 shares (+12.3%) to their portfolio in Q3 2025, for an estimated $1,119,771 $CADL

0 · Reply

CO145 Nov. 14 at 10:17 PM

$CADL bah ha ha. Citi takes target to 24 from 25. A whopping $1. Retail spooked institutions not.

0 · Reply

Spywest Nov. 14 at 10:12 PM

$CADL Baker Bros got rid of their last shares as I suspected. Few additions / Few sales from others - all in all not too much movement from institutions last quarter.

1 · Reply

graywolf Nov. 14 at 10:02 PM

$CADL Dr. PPT says he will go silent on social media, savvy bulls sense pending announcements and the crooks counter with misworded SA hit piece. Bring it on dummies!

0 · Reply

ak123456790 Nov. 14 at 9:28 PM

$CADL I remember some years ago that CADL were paying seeking alpha for promotion! What happened today ? Did CADL stopped paying them for advertisement and they started with shit news? Tak can easily sue them for posting misleading news..

0 · Reply

moneymaker444 Nov. 14 at 9:12 PM

$CADL 🤴🤴I've been telling moneymaker for months that when our ceo stfu on social media...that is when real substance come to fruition...post

0 · Reply

moneymaker444 Nov. 14 at 9:11 PM

$CADL🤴🤴I've been trading for a very very long time guys...before internet...all the way back to boil rooms...seeking alpha is a modern day boil room ...from my experience...whenever seeking alpha third party manipulate with false info..its usually a paid hit piece...always trust your own dd...and yes our ceo is in quiet period...best for ceo not to respond n not slip up...big moves maneuver in silence 😉 post

0 · Reply

fishmom Nov. 14 at 8:54 PM

$CADL We need a miracle to move SP higher?

1 · Reply

RaphaelRapoport Nov. 14 at 8:54 PM

$CADL Question/Theory. CEO Tak says hes getting off social... could this be because hes under NDA for a partnership deal and can no longer communicate online???

3 · Reply

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Nov 4, 2025, 9:00 AM EST - 10 days ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 11 days ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Oct 16, 2025, 8:05 AM EDT - 4 weeks ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 14, 2025, 8:10 AM EDT - 4 weeks ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 4 weeks ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 4 weeks ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 13, 2025, 10:22 AM EDT - 4 weeks ago

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now

Oct 3, 2025, 9:05 AM EDT - 6 weeks ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 6 weeks ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 2 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 7, 2025, 10:53 AM EDT - 2 months ago

Candel Therapeutics: Potentially The Next Exciting Oncology Story

Sep 5, 2025, 12:47 PM EDT - 2 months ago

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Sep 2, 2025, 8:05 AM EDT - 2 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 2 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 3 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 30, 2025, 8:05 AM EDT - 3 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 5 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

May 28, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 6 months ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 13, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Apr 23, 2025, 4:05 PM EDT - 7 months ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 8 months ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 8 months ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 20, 2025, 8:00 AM EDT - 8 months ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 18, 2025, 8:00 AM EDT - 8 months ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 13, 2025, 4:15 PM EDT - 8 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Feb 25, 2025, 4:52 PM EST - 9 months ago

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data

Feb 25, 2025, 8:00 AM EST - 9 months ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Feb 20, 2025, 10:45 AM EST - 9 months ago

Candel Therapeutics: Entering Its Pivotal Year

Jan 13, 2025, 8:00 AM EST - 10 months ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Jan 2, 2025, 11:46 PM EST - 11 months ago

Best-Performing Stocks Of 2024

APP BYRN DAVE INOD JANX LUNR MSTR

Dec 16, 2024, 4:01 PM EST - 11 months ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 8:53 AM EST - 1 year ago

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

EGHT

Dec 12, 2024, 11:00 PM EST - 1 year ago

Candel Therapeutics Announces Pricing of Public Offering

Dec 12, 2024, 4:51 PM EST - 1 year ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 11, 2024, 12:19 PM EST - 1 year ago

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Dec 11, 2024, 9:19 AM EST - 1 year ago

Candel Therapeutics Stock Surges Over 100% - Here's Why

Dec 11, 2024, 7:09 AM EST - 1 year ago

Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:00 AM EST - 1 year ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Nov 5, 2024, 9:00 AM EST - 1 year ago

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Nov 1, 2024, 12:40 PM EDT - 1 year ago

Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

Jul 29, 2024, 3:32 PM EDT - 1 year ago

3 Biotech Names With Potential Catalysts By Year End

RCKT VRDN

Kingjake26 Nov. 14 at 10:48 PM

ACORN CAPITAL ADVISORS, LLC added 428,265 shares (+19.9%) to their portfolio in Q2 2025, for an estimated $2,167,020 $CADL. Some funds added. Some sold. This was a big add

0 · Reply

Kingjake26 Nov. 14 at 10:48 PM

VANGUARD GROUP INC added 219,563 shares (+12.3%) to their portfolio in Q3 2025, for an estimated $1,119,771 $CADL

0 · Reply

CO145 Nov. 14 at 10:17 PM

$CADL bah ha ha. Citi takes target to 24 from 25. A whopping $1. Retail spooked institutions not.

0 · Reply

Spywest Nov. 14 at 10:12 PM

$CADL Baker Bros got rid of their last shares as I suspected. Few additions / Few sales from others - all in all not too much movement from institutions last quarter.

1 · Reply

graywolf Nov. 14 at 10:02 PM

$CADL Dr. PPT says he will go silent on social media, savvy bulls sense pending announcements and the crooks counter with misworded SA hit piece. Bring it on dummies!

0 · Reply

ak123456790 Nov. 14 at 9:28 PM

0 · Reply

moneymaker444 Nov. 14 at 9:12 PM

$CADL 🤴🤴I've been telling moneymaker for months that when our ceo stfu on social media...that is when real substance come to fruition...post

0 · Reply

moneymaker444 Nov. 14 at 9:11 PM

0 · Reply

fishmom Nov. 14 at 8:54 PM

$CADL We need a miracle to move SP higher?

1 · Reply

RaphaelRapoport Nov. 14 at 8:54 PM

$CADL Question/Theory. CEO Tak says hes getting off social... could this be because hes under NDA for a partnership deal and can no longer communicate online???

3 · Reply

RaphaelRapoport Nov. 14 at 8:53 PM

$CADL Wheres the slander law suits?

0 · Reply

CAN_2409 Nov. 14 at 8:27 PM

$CADL

1 · Reply

Heroforest Nov. 14 at 8:05 PM

$CADL we are at PPT's recent purchase price. going lower, means you have a better entry than the company's ceo..... so let's move there!!!

1 · Reply

Goldenpoint9 Nov. 14 at 7:59 PM

$CADL

0 · Reply

JarvisFlow Nov. 14 at 7:57 PM

Citigroup has updated their rating for Candel Therapeutics ( $CADL ) to Buy with a price target of 24.

0 · Reply

claybridge Nov. 14 at 7:39 PM

$CADL I posted a comment on SA and shamed him a tad on X.

0 · Reply

moneymaker444 Nov. 14 at 7:28 PM

$CADL 2026 year of the fire horse . Whos ready to ride 🤑

1 · Reply

moneymaker444 Nov. 14 at 7:05 PM

$CADL king again....When seeking alpha start posting bullshit...and ceo on quiet period...we GOOD GOOD POST

0 · Reply

moneymaker444 Nov. 14 at 7:03 PM

$CADL king responds ...Tell them seeking alpha false information...pause is pancreatic and looking for cash infusion like KING BEEN SAYING ..POST

0 · Reply

Timmyyy Nov. 14 at 6:57 PM

$CADL wrong, pausing PDAC to focus on BLA prostate and launch of phase 3 NSCLC

3 · Reply

Dodva Nov. 14 at 6:56 PM

$CADL Don’t go into the weekend without short shares. you wake up Monday to another fortune. meanwhile i will hold

1 · Reply

moneymaker444 Nov. 14 at 6:43 PM

$CADL From king .....They waiting for outside funding..post

1 · Reply

Market Cap	270.08M
Revenue (ttm)	0.00
Net Income (ttm)	-55.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.08

Volume	553,995
Avg Vol	780,022
Day's Range	N/A - N/A
Shares Out	54.90M
Stochastic %K	15%
Beta	-0.94
Analysts	Strong Sell
Price Target	$19.43